Clinical Trial Design and Regulatory Requirements for Artificial Intelligence as a Medical Device: A PRISMA-ScR-Guided Scoping Review of Global Guidance and Evidence (2017-2025).
PMID : 41827353 ·
U, m, a, m, a, h, e, s, w, a, r, i, , S, h, a, n, m, u, g, a, m, ;, , M, o, h, a, n, , K, u, m, a, r, , R, a, j, e, n, d, r, a, n, ;, , J, a, w, a, h, a, r, , N, a, t, a, r, a, j, a, n, ;, , V, e, e, r, a, , V, e, n, k, a, t, a, , S, a, t, y, a, n, a, r, a, y, a, n, a, , R, e, d, d, y, , K, a, r, r, i
Publicité
Résumé
Background: Artificial Intelligence as a Medical Device (AIaMD) introduces regulatory, methodological, ethical, and clinical challenges that are not fully addressed by traditional device trial frameworks. Given rapidly evolving and jurisdiction-specific guidance, a consolidated mapping of trial design expectations and regulatory requirements is needed. Objective: To map regulatory requirements and clinical trial design approaches for AIaMD across major jurisdictions and to identify key methodolo
Publicité
Source officielle
Voir sur PubMed →Données issues de PubMed / NCBI. Pour le texte intégral et les informations les plus récentes, consultez toujours la notice officielle.